Tricetin, a Dietary Flavonoid, Inhibits Proliferation of Human Breast Adenocarcinoma MCF-7 Cells by Blocking Cell Cycle Progression and Inducing Apoptosis

2009 ◽  
Vol 57 (18) ◽  
pp. 8688-8695 ◽  
Author(s):  
Ya-Ling Hsu ◽  
Yih-Huei Uen ◽  
Yi Chen ◽  
Hsin-Lin Liang ◽  
Po-Lin Kuo
2006 ◽  
Vol 9 (5) ◽  
pp. 1-4
Author(s):  
C. M. McNeil ◽  
E. A. Musgrove

Citation of original article:S. Mukherjee, S. E. Conrad.Journal of Biological Chemistry2005;280: 17616–17625.Abstract of the original article:Oestrogen rapidly induces expression of the proto-oncogene c-Myc. c-Myc is required for oestrogen-stimulated proliferation of breast cancer cells, and deregulated c-Myc expression has been implicated in antioestrogen resistance. In this report, we investigate the mechanism(s) by which c-Myc mediates oestrogen-stimulated proliferation and contributes to cell cycle progression in the presence of antioestrogen. The MCF-7 cell line is a model of oestrogen-dependent, antioestrogen-sensitive human breast cancer. Using stable MCF-7 derivatives with inducible c-Myc expression, we demonstrated that in antioestrogen-treated cells, the elevated mRNA and protein levels of p21WAF1/CIP1, a cell cycle inhibitor, decreased upon either c-Myc induction or oestrogen treatment. Expression of p21 blocked c-Myc-mediated cell cycle progression in the presence of antioestrogen, suggesting that the decrease in p21WAF1/CIP1is necessary for this process. Using RNA interference to suppress c-Myc expression, we further established that c-Myc is required for oestrogen-mediated decreases in p21WAF1/CIP1. Finally, we observed that neither c-Myc nor p21WAF1/CIP1is regulated by oestrogen or antioestrogen in an antioestrogen-resistant MCF-7 derivative. The p21 levels in the antioestrogen-resistant cells increased when c-Myc expression was suppressed, suggesting that loss of p21 regulation was a consequence of constitutive c-Myc expression. Together, these studies implicate p21WAF1/CIP1as an important target of c-Myc in breast cancer cells and provide a link between oestrogen, c-Myc, and the cell cycle machinery. They further suggest that aberrant c-Myc expression, which is frequently observed in human breast cancers, can contribute to antioestrogen resistance by altering p21WAF1/CIP1regulation.


1997 ◽  
Vol 234 (2) ◽  
pp. 293-299 ◽  
Author(s):  
Wei-Yong Zhu ◽  
Carol S. Jones ◽  
Andras Kiss ◽  
Karen Matsukuma ◽  
Sonal Amin ◽  
...  

Planta Medica ◽  
2005 ◽  
Vol 71 (3) ◽  
pp. 237-243 ◽  
Author(s):  
Po-Lin Kuo ◽  
Ya-Ling Hsu ◽  
Ta-Chen Lin ◽  
Liang-Tzung Lin ◽  
Jiunn-Kae Chang ◽  
...  

Author(s):  
Zhi Hung Yap ◽  
Wei Yang Kong ◽  
Abdur Rahmaan Azeez ◽  
Chee-Mun Fang ◽  
Siew Ching Ngai

Background: High relapse and metastasis progression in breast cancer patients have prompted the need to explore alternative treatments. Epigenetic therapy has emerged as an attractive therapeutic strategy due to the reversibility of epigenome structures. Objective: This study investigated the anti-cancer effects of epigenetic drugs scriptaid and zebularine in human breast adenocarcinoma MDA-MB-231 and MCF-7 cells. Methods: First, the half maximal inhibitory concentration (IC50) of scriptaid, zebularine and the combination of both drugs on human breast adenocarcinoma MDA-MB-231 cells was determined. Next, MDA-MB-231 and MCF-7 cells were treated with scriptaid, zebularine and the combination of both. After treatments, the anti-cancer effects were evaluated via cell migration assay, cell cycle analysis and apoptotic studies, which included histochemical staining and reverse-transcriptase polymerase chain reaction (RT-PCR) of the apoptotic genes. Results: Both epigenetic drugs inhibited cell viability in a dose-dependent manner with 2 nM scriptaid, 8 µM zebularine and combination of 2 nM scriptaid and 2 µM zebularine. Both MDA-MB-231 and MCF-7 cells exhibited a reduction in cell migration after the treatments. In particular, MDA-MB-231 cells exhibited a significant reduction in cell migration (p < 0.05) after the treatments of zebularine and the combination of scriptaid and zebularine. Besides, cell cycle analysis demonstrated that scriptaid and the combination of both drugs could induce cell cycle arrest at the G0/G1 phase in both MDA-MB-231 and MCF-7 cells. Furthermore, histochemical staining allowed the observation of apoptotic features, such as nuclear chromatin condensation, cell shrinkage, membrane blebbing, nuclear chromatin fragmentation and cytoplasmic extension, in both MDA-MB-231 and MCF-7 cells after the treatments. Further apoptotic studies revealed that the upregulation of pro-apoptotic Bax, downregulation of anti-apoptotic Bcl-2 and elevation of Bax/Bcl-2 ratio were found in MDA-MB-231 cells treated with zebularine and MCF-7 cells treated with all drug regimens. Conclusion: Collectively, these findings suggest that scriptaid and zebularine are potential anti-cancer drugs, either single or in combination, for the therapy of breast cancer. Further investigations of the gene regulatory pathways directed by scriptaid and zebularine are definitely warranted in the future.


2005 ◽  
Vol 203 (1) ◽  
pp. 85-93 ◽  
Author(s):  
Rania Kairouz ◽  
Jayamala Parmar ◽  
Ruth J. Lyons ◽  
Alexander Swarbrick ◽  
Elizabeth A. Musgrove ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document